Table 3. Patient characteristics and... | American Society of Hematology

Table 3.

Patient characteristics and outcomes for common disease groups and subgroups

Disease group or subgroup	n	Median age (range), y	Median HCT-CI (range)	MRD, %	Median follow-up, y	4-y OS, %	4-y PFS, %
AML	193	62 (23-78)	2 (0-9)	46	5.83	42	32
Cytogenetic/molecular risk
Intermediate risk	119	61 (29-74)	2 (0-6)	49	6.52	48	36
Adverse risk*	74	63 (23-78)	2 (0-9)	42	3.99	32	24
Remission status
CR1	146	62 (39-73)	2 (0-9)	47	5.66	44	33
CR2	32	62 (23-74)	1 (0-6)	47	7.54	37	31
Beyond CR2	15	64 (45-78)	2 (0-4)	33	3.92	27	13
MDS	94	64 (37-74)	3 (0-6)	41	4.64	30	21
IPSS-R risk
Intermediate risk	27	63 (50-74)	2 (0-5)	37	4.40	57	41
High or very high risk	67	64 (37-72)	3 (0-6)	42	5.05	20	14
Blast % at time of HCT
<5% blasts	69	63 (37-74)	3 (0-6)	45	4.64	34	27
≥5% blasts	25	64 (50-72)	3 (0-5)	28	5.12	19	8
CLL	80	56 (31-77)	1 (0-5)	39	7.76	67	43
Cytogenetic risk
Standard risk	33	54 (31-66)	1 (0-4)	39	9.01	72	51
High risk†	47	58 (38-77)	2 (0-5)	41	6.75	63	36
Remission status
CR	17	55 (34-68)	1 (0-3)	24	7.49	66	55
PR/SD/PD	63	56 (31-77)	1 (0-5)	44	8.02	67	39
NHL	175	56 (27-72)	2 (0-8)	49	6.23	68	45
Lymphoma subtype
Indolent B-cell lymphoma‡	34	54 (35-69)	1 (0-7)	59	6.04	82	61
DLBCL	66	56 (27-72)	2 (0-8)	48	5.85	70	44
Mantle cell lymphoma	53	61 (41-71)	2 (0-6)	43	10.0	58	31
T-cell lymphoma	22	56 (28-72)	2 (0-6)	45	4.10	63	59
Remission status
CR	96	58 (28-72)	2 (0-7)	50	6.02	71	49
PR/SD/PD	79	54 (27-72)	1 (0-8)	47	8.05	64	42
HL	35	29 (21-59)	1 (0-6)	40	4.97	78	49

Disease group or subgroup	n	Median age (range), y	Median HCT-CI (range)	MRD, %	Median follow-up, y	4-y OS, %	4-y PFS, %
AML	193	62 (23-78)	2 (0-9)	46	5.83	42	32
Cytogenetic/molecular risk
Intermediate risk	119	61 (29-74)	2 (0-6)	49	6.52	48	36
Adverse risk*	74	63 (23-78)	2 (0-9)	42	3.99	32	24
Remission status
CR1	146	62 (39-73)	2 (0-9)	47	5.66	44	33
CR2	32	62 (23-74)	1 (0-6)	47	7.54	37	31
Beyond CR2	15	64 (45-78)	2 (0-4)	33	3.92	27	13
MDS	94	64 (37-74)	3 (0-6)	41	4.64	30	21
IPSS-R risk
Intermediate risk	27	63 (50-74)	2 (0-5)	37	4.40	57	41
High or very high risk	67	64 (37-72)	3 (0-6)	42	5.05	20	14
Blast % at time of HCT
<5% blasts	69	63 (37-74)	3 (0-6)	45	4.64	34	27
≥5% blasts	25	64 (50-72)	3 (0-5)	28	5.12	19	8
CLL	80	56 (31-77)	1 (0-5)	39	7.76	67	43
Cytogenetic risk
Standard risk	33	54 (31-66)	1 (0-4)	39	9.01	72	51
High risk†	47	58 (38-77)	2 (0-5)	41	6.75	63	36
Remission status
CR	17	55 (34-68)	1 (0-3)	24	7.49	66	55
PR/SD/PD	63	56 (31-77)	1 (0-5)	44	8.02	67	39
NHL	175	56 (27-72)	2 (0-8)	49	6.23	68	45
Lymphoma subtype
Indolent B-cell lymphoma‡	34	54 (35-69)	1 (0-7)	59	6.04	82	61
DLBCL	66	56 (27-72)	2 (0-8)	48	5.85	70	44
Mantle cell lymphoma	53	61 (41-71)	2 (0-6)	43	10.0	58	31
T-cell lymphoma	22	56 (28-72)	2 (0-6)	45	4.10	63	59
Remission status
CR	96	58 (28-72)	2 (0-7)	50	6.02	71	49
PR/SD/PD	79	54 (27-72)	1 (0-8)	47	8.05	64	42
HL	35	29 (21-59)	1 (0-6)	40	4.97	78	49

Patients with complex cytogenetics, monosomy 5 or 7, del(17p), inv(3), t(3;3), or t(6;9) or mutated RUNX1, ASXL1, or TP53.

Patients with del(11q) or del(17p).

Follicular lymphoma (n = 22), marginal zone lymphoma (n = 7), and lymphoplasmacytic lymphoma (n = 5).